Table 4.
Base case analysis results
| Year 1 | Year 2 | Year 3 | |
|---|---|---|---|
| Total costs | |||
| Without vericiguat | $351,207,596 | $365,045,892 | $385,313,354 |
| Drug acquisition | $21,390,120 | $23,269,360 | $25,371,024 |
| HF hospitalization | $209,462,276 | $175,278,674 | $151,855,028 |
| Routine care | $72,863,504 | $79,264,965 | $86,424,091 |
| Terminal care | $47,491,696 | $87,232,893 | $121,663,211 |
| With vericiguat | $356,971,870 | $372,682,039 | $395,639,395 |
| Drug acquisition | $28,433,582 | $32,044,875 | $36,937,022 |
| HF hospitalization | $208,407,967 | $174,513,465 | $151,133,033 |
| Routine care | $72,877,352 | $79,302,706 | $86,481,352 |
| Terminal care | $47,252,969 | $86,820,993 | $121,087,988 |
| Total budget impact | $5764,274 | $7636,147 | $10,326,041 |
| Drug acquisition | $7043,461 | $8,775,515 | $11,565,999 |
| HF hospitalization | − $1054,309 | − $765,210 | − $721,996 |
| Routine care a | $13,848 | $37,742 | $57,261 |
| Terminal care | − $238,727 | − $411,900 | − $575,223 |
| Other budget impact measures | |||
| PMPM | $0.048 | $0.064 | $0.086 |
| PMPY | $0.576 | $0.764 | $1.033 |
| PPPM | $23 | $27 | $32 |
| PPPY | $281 | $323 | $386 |
| Total number of events | |||
| Without vericiguat | |||
| HF hospitalization | 8874 | 7426 | 6433 |
| CV mortality | 1494 | 2745 | 3828 |
| With vericiguat | |||
| HF hospitalization | 8829 | 7393 | 6403 |
| CV mortality | 1487 | 2732 | 3810 |
| Number of events avoidedb | |||
| HF hospitalization | 44 | 32 | 30 |
| CV mortality | 7 | 12 | 18 |
CV cardiovascular, HF heart failure, PMPM per member per month, PMPY per member per year, PPPM per patient per month, PPPY per patient per year
aIntroduction of vericiguat was associated with increased total costs of routine care because patients receiving vericiguat had longer life expectancy to incur more routine care costs
bThe number of events avoided were rounded down to be conservative